Magnetic Fields / TRAIL Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱

Features: Therapy

Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Reactive oxygen species (ROS)	↑ ROS (P→R); often sustained (G)	↑ ROS (P); ↔/↓ net ROS (R→G)	P, R, G	Upstream redox perturbation	MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2	NRF2 antioxidant response	↔ / insufficient NRF2 induction (R→G)	↑ NRF2 activation (R→G)	R, G	Adaptive redox defense	Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3	Glutathione (GSH) homeostasis	↓ GSH (R→G)	↔ or transient ↓ (R) with recovery (G)	R, G	Redox buffering capacity	GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4	Superoxide dismutase (SOD) / antioxidant enzymes	↔ or inadequate enzyme upshift (G)	↑ SOD/GPx/CAT capacity (G)	G	Longer-term antioxidant remodeling	Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5	Mitochondrial ETC / respiration	↓ ETC efficiency; ↑ electron leak (P→R)	↔ mild, reversible ETC perturbation (P→R)	P, R	Bioenergetic destabilization	ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6	Mitochondrial membrane potential (ΔΨm / MMP)	↓ ΔΨm (R); may progress (G)	↔ preserved or reversible dip (R)	R, G	Mitochondrial dysfunction thresholding	ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7	Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux)	↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G)	↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G)	P, R, G	Stress signal amplification	Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8	Mitochondrial permeability transition pore (MPTP)	↑ MPTP opening propensity (R); sustained opening possible (G)	↔ transient or closed (R→G)	P, R, G	Commitment point for mitochondrial failure	MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9	ER stress / UPR	↑ ER stress (R); CHOP-commitment possible (G)	↑ adaptive UPR (R); resolves (G)	R, G	Proteostasis stress	Often downstream of ROS + Ca²⁺ handling perturbations
10	DNA damage (oxidative)	↑ damage markers (R→G)	↔ or repaired (G)	R, G	Checkpoint pressure	Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11	LDH / glycolytic flux	↓ glycolytic performance (R→G)	↔ flexible substrate switching (R→G)	R, G	Metabolic vulnerability	Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12	Thioredoxin system (Trx / TrxR)	↓ functional reserve / overload (R→G)	↔ preserved capacity (G)	R, G	Parallel antioxidant system stress	Useful when GSH-only does not explain redox phenotype

Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)

MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.

TRAIL, tumor necrosis factor-related apoptosis-inducing ligand: Click to Expand ⟱

Source:

Type:

TRAIL (TNF-related apoptosis-inducing ligand) is a protein that plays a significant role in the regulation of apoptosis, or programmed cell death. It is part of the tumor necrosis factor (TNF) superfamily and has garnered interest in cancer research due to its ability to selectively induce apoptosis in cancer cells while sparing normal cells.
TRAIL binds to specific receptors on the surface of cells, known as TRAIL receptors (TRAIL-R1 and TRAIL-R2), which triggers a cascade of signaling events leading to apoptosis. This selective action makes TRAIL a potential therapeutic agent for cancer treatment.
TRAIL has been studied as a potential targeted therapy for various cancers, including breast, prostate, and lung cancer. Researchers are exploring ways to enhance its effectiveness, such as combining TRAIL with other treatments (chemotherapy, radiation) or using TRAIL in engineered forms (like TRAIL receptor agonists).

Scientific Papers found: Click to Expand⟱

3458-

MF,

Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy

in-vitro,

GBM,

65 mT and 50 Hz for 30 min

ER Stress↑, UPR↑, Ca+2↑, TRAIL↓, GRP78/BiP↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

TRAIL↓, 1,

Protein Folding & ER Stress ⓘ

ER Stress↑, 1, GRP78/BiP↑, 1, UPR↑, 1,

Migration ⓘ

Ca+2↑, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells